Suggestions
Jurgen Kuball
Chair of the Department of Hematology, Principle Investigator
Jurgen Kuball is a prominent figure in the field of hematology and immunology. He holds the position of Professor and Chair of the Department of Hematology at the UMC Utrecht Cancer Centre.1 His clinical activities primarily focus on acute leukemia and allogeneic treatments.
Research and Expertise
Dr. Kuball is actively involved in cutting-edge research and development in the following areas:
- Immunotherapy: He is engaged in projects developing γδT cell-based therapeutics, as evidenced by recently funded KWF projects.5
- CAR-T Cell Therapy: Kuball is involved in the implementation and study of CAR-T cell treatments, celebrating milestones such as the registration of 9,000 patients treated with CAR-T cells in the EBMT registry.6
- Cell and Gene Therapy: He recognizes the potential for cell and gene therapy in the Netherlands and is involved in initiatives supported by Oncode Accelerator.3
Professional Activities
Dr. Kuball actively participates in academic and professional events:
- He attended the AACR24 conference, where he was part of a session on engineered immune cells beyond CAR-T.2
- He is involved in surveys and discussions about the state-of-the-art ATMP (Advanced Therapy Medicinal Products) development.4
Funding and Recognition
Kuball's work has attracted significant funding and recognition:
- He, along with colleague Moniek de Witte, received a €150,000 donation from the Leukemia Foundation for their research.7
Through his leadership roles, research contributions, and active engagement in the field, Jurgen Kuball is making significant strides in advancing hematology and immunology at UMC Utrecht and beyond.
Highlights
Ben jij een ambitieuze hematoloog met affiniteit voor academische klinische patiëntenzorg? Sluit je aan bij ons team, waar je patiënten met oncologische hematologische ziektebeelden zult behandelen en supervisie geeft aan arts-assistenten & PA's.
Last days of a survey on state of the art ATMP development and future needs if the field. Viral or non viral gene transfer ? Technology we have and we will need to develop. A collaboration of GoCART Coalition T2EVOLVE Consortium The EBMT NextgenHightech. Please participate: One participant per hospital / organization needed.
